MPO and ganglioneuroma: In a murine model expressing the human C5a receptor, treatment with avacopan was able to abrogate the development of pauci-immune necrotizing and crescentic GN following passive transfer of antibodies to mouse myeloperoxidase.S4 In addition, staining for C5b-9 on renal biopsies is positive in most patients with ANCA GN, confirming that complement activation occurs in human disease.S5 In the ADVOCATE trial, patients randomized to avacopan had more rapid reductions in albuminuria and greater recovery of eGFR despite a significant reduction in glucocorticoid exposure.